Literature DB >> 7641021

Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

R R Perry1, Y Kang, B Greaves.   

Abstract

BACKGROUND: Apoptosis ("programmed cell death") is an active process characterized by prominent nuclear changes and DNA cleavage, which distinguishes it from cellular necrosis. In this study we investigated whether tamoxifen (TAM) treatment of estrogen receptor ER(+) MCF-7 and ER(-) MDA-231 human breast cancer cells resulted in cytotoxicity and cellular changes typical of apoptosis.
METHODS: Cytotoxicity was measured using a tetrazolium assay. Cellular morphologic changes were observed using transmission electron microscopy. DNA cleavage was assessed using 1.6% agarose gel electrophoresis and was also quantitated biochemically.
RESULTS: Exposure of cells to TAM for 24 h resulted in dose-dependent cytotoxicity, and MCF-7 cells were somewhat more sensitive to TAM. TAM induced chromatin condensation around the nuclear periphery in both cell lines, changes typical of apoptosis. TAM-induced cytotoxicity correlated with dose-dependent DNA cleavage, which showed the characteristic "internucleosomal ladder." DNA cleavage occurred at a slightly lower TAM dose and occurred somewhat sooner in MCF-7 cells. TAM-induced DNA cleavage in MCF-7 cells was inhibited by the protein synthesis inhibitor cycloheximide, the RNA synthesis inhibitor actinomycin D, and by 17 beta-estradiol. However, in MDA-231 cells, DNA cleavage was inhibited by cycloheximide, partially but not significantly inhibited by actinomycin D, and not inhibited by 17 beta-estradiol.
CONCLUSIONS: TAM induces typical apoptosis in ER(+) or ER(-) human breast cancer cells. TAM induction of apoptosis in MCF-7 cells involves the estrogen receptor, and requires the synthesis of new protein and mRNA. TAM induction of apoptosis in MDA-231 cells depends primarily on protein synthesis. TAM-induced cytotoxicity and DNA damage appear to be explained in part by the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641021     DOI: 10.1007/bf02307030

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

Review 1.  Identification of genes involved in programmed cell death.

Authors:  G P Owens; J J Cohen
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Induction of apoptosis in fibroblasts by c-myc protein.

Authors:  G I Evan; A H Wyllie; C S Gilbert; T D Littlewood; H Land; M Brooks; C M Waters; L Z Penn; D C Hancock
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

3.  Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells.

Authors:  R J Rotello; R C Lieberman; A F Purchio; L E Gerschenson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes.

Authors:  D L Evans; C Dive
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

6.  Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

Authors:  C M Taylor; B Blanchard; D T Zava
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Apoptosis in cultured rat hepatocytes: the effects of tumour necrosis factor alpha and interferon gamma.

Authors:  T Shinagawa; K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

8.  Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.

Authors:  A M Wärri; R L Huovinen; A M Laine; P M Martikainen; P L Härkönen
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

Review 9.  Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.

Authors:  R R Love
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

10.  Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.

Authors:  J Kirk; S Houlbrook; N S Stuart; I J Stratford; A L Harris; J Carmichael
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more
  41 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Authors:  Stephanie J Byer; Jenell M Eckert; Nicole M Brossier; Buffie J Clodfelder-Miller; Amy N Turk; Andrew J Carroll; John C Kappes; Kurt R Zinn; Jeevan K Prasain; Steven L Carroll
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

3.  In Vitro Investigations on the Toxicity and Cell Death Induced by Tamoxifen on Two Non-Breast Cancer Cell Types.

Authors:  S. K. Majumdar; J. A. Valdellon; K. A. Brown
Journal:  J Biomed Biotechnol       Date:  2001

4.  An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells.

Authors:  YuMing Guo; XinTian Zhang; Jun Meng; Zhao-Yi Wang
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

Review 5.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 6.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

7.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

8.  Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells.

Authors:  Gunjan Gakhar; Duy H Hua; Thu Annelise Nguyen
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

9.  Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice.

Authors:  Yoshiaki Kanaya; Hiroyoshi Doihara; Kouji Shiroma; Yutaka Ogasawara; Hiroshi Date
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

10.  Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia.

Authors:  Wolfgang Glienke; Yuliya Dolgova; Iris Müller; Sabine Grösch; Jochen Binder; Gerd Geisslinger; Dietger Jonas
Journal:  World J Urol       Date:  2004-09-23       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.